The U.S. Food and Drug Administration approved Novavax’s COVID-19 vaccine, but limited its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness.
(Reuters) -Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no ...
WASHINGTON — Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 vaccine, albeit with new conditions. The Food and Drug Administration ...
Investors with a lot of money to spend have taken a bearish stance on Novavax NVAX. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...
Novavax, Inc. (NASDAQ:NVAX) ranks among the most oversold biotech stocks to invest in. Novavax, Inc. (NASDAQ:NVAX) announced its third-quarter 2025 financial results on November 6, emphasizing the ...
The Food and Drug Administration has granted full approval to Novavax, Inc. (NASDAQ:NVAX) COVID-19 vaccine, but with notable limitations. Previously available under emergency use authorization for ...
Hosted on MSN
Why I wouldn't touch Novavax with a 10-foot pole
Novavax faces plenty of uncertainty related to a deal it signed with a larger company. The biotech's pipeline doesn't look that exciting either. 10 stocks we like better than Novavax › Novavax (NASDAQ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results